{
    "clinical_study": {
        "@rank": "70639", 
        "arm_group": [
            {
                "arm_group_label": "Herceptin/Perjeta (trastuzumab/pertuzumab)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Tarceva (erlotinib)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Zelboraf (vemurafenib)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Erivedge (vismodegib)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, non-randomized, open-label study designed to evaluate fou r treatment\n      regimens in patients with advanced cancer for whom there is no avail able, beneficial\n      treatment. Patients with HER2 overexpression, amplification, or\n\n        -  activating mutation will be treated with Herceptin/Perjeta; those with epiderm al\n           growth factor receptor (EGFR), with Tarceva; those with BRAF-activating mutat ion, with\n           Zelboraf; and those with Hedehog pathway potentially clinically releva nt mutation,\n           with Erivedge. Treatment will continue until disease progression or unacceptable\n           toxicity occurs. Study is expected to last up to 5 years."
        }, 
        "brief_title": "A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >/= 18 years\n\n          -  Life expectancy >/= 12 weeks\n\n          -  Histologically documented metastatic cancer (solid tumors, not including hematologic\n             malignancies)\n\n          -  Molecular testing results from certified laboratories (using tissue from the most\n             recent tumor biopsy in the metastatic setting) that show at least one of the\n             following abnormalities:\n\n          -  HER2 overexpression, amplification, or HER2-activating mutation\n\n          -  EGFR-activating mutation\n\n          -  BRAF-activating mutation\n\n          -  Hedgehog pathway potentially clinically relevant mutation (activating mutation of SMO\n             or loss-of-function mutation of PTCH-1)\n\n          -  Patients who have received standard first-line therapy for metastatic cancer (except\n             for the tumors for which no first-line therapy exists) and in whom a trial of\n             targeted therapy is considered the best available treatment option. Eligible patients\n             should not have available therapies that will convey clinical benefit.\n\n          -  No previous treatment with the specific assigned study drug or any other drug sharing\n             the same target\n\n          -  Progressive cancer at the time of study entry\n\n          -  Measurable or evaluable disease by RECIST v. 1.1\n\n          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0, 1, or 2\n\n          -  Adequate hematologic, renal, and liver function\n\n          -  Use of effective contraception as defined by the protocol\n\n        Study-drug specific criteria:\n\n          -  Trastuzumab plus Pertuzumab\n\n          -  Patients with solid tumors that have HER2 overexpression, amplification, or\n             HER2-activating mutation\n\n          -  Patients with breast, gastric, or gastroesophageal junction cancer must have\n             HER2-activating mutation.\n\n          -  Left ventricular ejection fraction (LVEF) > 50% or above the lower limit of the\n             institutional normal range, whichever is lower\n\n          -  Erlotinib\n\n          -  Patients with solid tumors that harbor EGFR-activating mutations\n\n          -  Vemurafenib\n\n          -  BRAF mutation positivity as determined by next generation sequencing (NGS) or real\n             time-polymerase chain reaction (RT-PCR) will be accepted.\n\n          -  Vismodegib\n\n          -  Hedgehog-activating mutation positivity\n\n          -  All non-hematological adverse events related to any prior chemotherapy, surgery, or\n             radiotherapy must have resolved to National Cancer Institute Common Terminology\n             Criteria for Adverse Events (NCI CTCAE) Grade </= 2 prior to starting therapy.\n\n        Exclusion Criteria:\n\n          -  Patients with hematologic malignancies\n\n          -  Concurrent administration of any other anti-cancer therapy\n\n          -  Bisphosphonates and denosumab are allowed.\n\n          -  Most recent anti-cancer therapy </= 28 days or have not recovered from the side\n             effects, excluding alopecia\n\n          -  Active or untreated brain metastases\n\n          -  History of carcinomatous meningitis\n\n          -  Uncontrolled concurrent malignancy (early stage is allowed if not requiring active\n             therapy or intervention)\n\n          -  Women who are breastfeeding or pregnant\n\n          -  Any significant cardiovascular events within 6 months prior to study entry.\n\n          -  Pulmonary embolism within 30 days prior to study entry\n\n          -  History or presence of clinically significant ventricular or atrial dysrhythmia\n             >Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events\n             version 4.0 [NCI CTCAE v4.0])\n\n          -  Any other severe acute or chronic medical or psychiatric condition or laboratory\n             abnormality\n\n          -  Eligible for another actively accruing Roche/Genentech-sponsored interventional\n             clinical trial\n\n        Study-drug specific criteria:\n\n          -  Trastuzumab plus Pertuzumab\n\n          -  Breast, gastric, or gastroesophageal junction cancer identified by HER2 amplification\n             or overexpression\n\n          -  Previous treatment with any HER2-targeted therapy\n\n          -  Erlotinib\n\n          -  Non-small cell lung cancer (NSCLC) or pancreatic cancer identified by exon 19 and\n             exon 21 mutations\n\n          -  Cancers with exon 20 mutations\n\n          -  Previous treatment with erlotinib or any other EGFR inhibitor\n\n          -  Vemurafenib\n\n          -  Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic\n             malignancy including multiple myeloma\n\n          -  Prior or concurrent malignancy with known RAS mutation\n\n          -  Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is\n             allowed)\n\n          -  Prior treatment with a MEK inhibitor\n\n          -  Corrected QT (QTc) interval &#8805; 450 msec at baseline or history of congenital\n             long QT syndrome\n\n          -  Vismodegib\n\n          -  Basal cell carcinoma of the skin, medulloblastoma, small-cell lung cancer, or\n             hematologic malignancies\n\n          -  Previous treatment with vismodegib or any other hedgehog pathway inhibitor\n\n          -  Breast cancer patients taking hormone replacement therapy or hormonal birth control"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091141", 
            "org_study_id": "ML28897"
        }, 
        "intervention": [
            {
                "arm_group_label": "Herceptin/Perjeta (trastuzumab/pertuzumab)", 
                "description": "An 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg, given by IV infusion every 3 weeks", 
                "intervention_name": "Trastuzumab [Herceptin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin/Perjeta (trastuzumab/pertuzumab)", 
                "description": "An 840 mg IV loading dose, followed by 420 mg, given by IV every 3 weeks", 
                "intervention_name": "Pertuzumab [Perjeta]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tarceva (erlotinib)", 
                "description": "A daily dose of 150 mg given orally in cycles of 28 days (4 weeks) duration", 
                "intervention_name": "Erlotinib [Tarceva]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Zelboraf (vemurafenib)", 
                "description": "960 mg given twice-daily (BID) orally in cycles of 28 days (4 weeks) duration", 
                "intervention_name": "Vemurafenib [Zelboraf]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Erivedge (vismodegib)", 
                "description": "A daily dose of 150 mg given orally in cycles of 28 days (4 weeks) duration", 
                "intervention_name": "Vismodegib [Erivedge]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trastuzumab", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft Myers", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28897 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate as determined by the investigator according to response evaluation in solid tumors (RECIST) v. 1.1 criteria", 
            "safety_issue": "No", 
            "time_frame": "Approximately 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091141"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease control rate, defined as the proportion of patients whose best response is complete response, partial response or stable disease", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 year"
            }, 
            {
                "measure": "Progression-free survival, defined as the time from first study treatment to until disease progression as assessed by the investigator, or death from any cause", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 year"
            }, 
            {
                "measure": "Overall survival, defined as the survival rate 1 year from the date of first treatment", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 year"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}